Melanoma vaccines show promiseBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7134.797e (Published 14 March 1998) Cite this as: BMJ 1998;316:797
- Deborah Josefson
- San Francisco
Two vaccines developed to fight melanoma have shown promise in early clinical trials. The vaccines were used in patients with advanced disease and work by enhancing a patient's immune response to the tumours.
A team led by Dr Steven Rosenberg of the National Cancer Institute in the United States constructed a vaccine based on gp100, a particularly immunogenic protein displayed on the surface of melanoma cells (Nature Medicine 1998;4:269-70). This was injected into 31 patients with metastatic melanoma who were subsequently treated with interleukin 2, a T …
Log in using your username and password
Log in through your institution
Sign up for a free trial